Millennium | Clinicians | Oncology | VELCADE

	Overview
	VELCADE^®
	Research and Development
	Clinical Trials
	Resources for Patients

Indication: VELCADE^® (bortezomib) for Injection is indicated for the treatment of patients with multiple myeloma who have received at least 1 prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy.

For further information about VELCADE and Multiple Myeloma (MM), select a menu item in the table below.

Menu Item	Topic
Mechanism	VELCADE: mechanism of action
Landmark, Phase 3 APEX Trial	Landmark, Phase 3 APEX Trial
Survival	Extend survival: most active single-agent in large randomized trial
Treatment Timing	Earlier treatment, improved results in APEX
Renal Impairment	Results in patients with renal impairment
Length of Therapy	Optimize treatment and outcomes
Retreatment	Emerging VELCADE retreatment data
Safety Profile	MM overall safety results and integrated safety analysis
Dose Modification Guidelines	Recommendations for managing side effects
Important Safety Information	Indication, contraindications, warnings, precautions, and support
Handling and Administration	Handling and administration guidelines
Reimbursement	Reimbursement assistance program
Additional Information	Downloadable files and phone number for VELCADE information
References	Journal articles and other cited sources